VOLUNTEER FOR RESEARCH
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Clinical Trial
BAcKGROUND
Glioblastoma (GBM) is the most common malignant brain tumor among adults. As the diagnosis is generally considered terminal, patients with GBM often suffer from anxiety and other comorbid conditions, including depression, pain, and sleep disturbance, all of which significantly impact their quality of life.
STUDY DETAILS
This study includes a double-blind, placebo-controlled, 8-week randomized clinical trial assessing the impact of a custom formulated, full-spectrum, hemp-derived ultra-high CBD product on measures of anxiety, pain, and quality of life in newly-diagnosed GBM patients undergoing standard of care (SOC) treatment; the impact of this product vs. placebo on tumor progression will also be assessed.
Visit https://clinicaltrials.gov/study/NCT05753007 for more information
RECRUITMENT INFORMATION
This study is in collaboration with, and taking place at, the University of California, San Francisco (UCSF).